In adults with ITP, which is commonly used as first-line therapy?

In adults with ITP, which is commonly used as first-line therapy?

• A. IVIG as initial therapy
• B. Platelet transfusion for all patients
• C. Corticosteroids
• D. Splenectomy as first-line

Answer: (C)

The main idea is to rapidly dampen the autoimmune destruction of platelets. In adults with ITP, corticosteroids are used first because they suppress the immune response, reduce autoantibody production, and blunt the destruction and clearance of platelets. This often leads to a quick increase in platelet counts and a decreased bleeding risk, which is why steroids like prednisone or a short course of high-dose dexamethasone are the standard initial therapy. IVIG is helpful when a rapid, but temporary, rise in platelets is needed or when steroids are contraindicated, but it isn’t chosen as the default first-line therapy for all patients because its effect is usually transient and it is more costly. Platelet transfusion is generally not effective as a routine first-line therapy because the autoantibodies continue to destroy transfused platelets, so it’s reserved for life-threatening bleeding or just before urgent procedures. Splenectomy addresses the primary site of platelet destruction but is invasive and carries long-term risks, so it’s considered after medical therapies have failed or in chronic, refractory cases, not as initial management.

The main idea is to rapidly dampen the autoimmune destruction of platelets. In adults with ITP, corticosteroids are used first because they suppress the immune response, reduce autoantibody production, and blunt the destruction and clearance of platelets. This often leads to a quick increase in platelet counts and a decreased bleeding risk, which is why steroids like prednisone or a short course of high-dose dexamethasone are the standard initial therapy.

IVIG is helpful when a rapid, but temporary, rise in platelets is needed or when steroids are contraindicated, but it isn’t chosen as the default first-line therapy for all patients because its effect is usually transient and it is more costly. Platelet transfusion is generally not effective as a routine first-line therapy because the autoantibodies continue to destroy transfused platelets, so it’s reserved for life-threatening bleeding or just before urgent procedures. Splenectomy addresses the primary site of platelet destruction but is invasive and carries long-term risks, so it’s considered after medical therapies have failed or in chronic, refractory cases, not as initial management.